A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?» Read More
Fed Chairman Ben Bernanke's testimony before a Senate committee takes on even greater importance for Tuesday's markets, now that the Fed and Treasury have promised to backstop mortgage giants Fannie Mae and Freddie Mac.
In Monday’s Web Extra the traders reveal how to play J&J earnings, retail numbers and other events likely to move the market, tomorrow!
Banks are oversold and cheap by historical standards, and while a few that report decent numbers will definitely bounce, it is unlikely to eliminate worries over more capital raising. There's additional worries, as now many are concerned with deterioration in other parts of the banks' portfolios...
To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now.
Futures were up pre-open, we started strong...and then faded away. It is not a good sign that financials--the very group that was supposed to be helped by the Fannie/Freddie news--are flat to down.
Here's our Fast Money Final Trade. Our gang gives you Monday's best trades, right now!
Also, how to play next week's busy schedule of earnings.
Is there any way that earnings could help Wall Street shake off the bear market blues next week?
Fearing the two largest U.S. mortgage finance companies need a government bailout, investors pushed stocks lower Friday. What's the "Word On The Street?"
Nearly 1.4 billion shares and over $16 billion traded yesterday in CNBC's Million Dollar Portfolio Challenge. Check out the bets being made today...
Former Citigroup Chairman and Chief Executive Chuck Prince has joined the Xerox board of directors, Xerox said on Thursday.
It's a booyah-free zone. There goes Swifty!
The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"
Wall Street is bracing for a big round of second-quarter earnings reports that few expect to deliver good news for the state of corporate America.
In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.
FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."
I had a visit on Power Lunch today and we talked about the effect on the health care stocks depending on who wins the White House. In general, pharmaceutical companies do well when they have a new product pipeline of innovative products that allow them to command high prices.
The week began with a flashback to the credit crisis. It ended with figures showing the fastest inflation in six months and the lowest consumer-sentiment reading in 28 years. Along the way, as the stock market ebbed and flowed, CNBC guests assembled a collective portfolio that was heavy on technology, energy, and global exposure.
CNBC asked the market experts where investors should be putting their money, and here are some of their best suggestions.
Robert Zagunis says investors should put their money into shares of diversified international companies: "where the action is."